Lip and Oral Cavity Squamous Cell Carcinoma, Oral Cavity Verrucous Carcinoma, Precancerous Condition
Conditions
Brief summary
This randomized phase II trial studies how well vandetanib works in preventing head and neck cancer in patients with precancerous head and neck lesions. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of vandetanib may keep cancer from forming in patients with premalignant lesions
Detailed description
PRIMARY OBJECTIVE: I. Determine the effect of ZD6474 (vandetanib) compared to placebo on microvessel density (MVD) from baseline to 3 months in patients at risk for oral squamous cell carcinoma (OSCC) with preneoplastic lesions. SECONDARY OBJECTIVES: I. Change in MVD over 6 months. II. Change in putative targets of ZD6474: tissues will be analyzed by immunohistochemistry (IHC) for phosphorylated epidermal growth factor receptor (pEGFR), EGFR, phosphorylated-vascular endothelial growth factor receptor 2 (pVEGFR2), VEGFR2. III. Change in proliferative index as measured by Ki-67 IHC. IV. Safety, tolerability, and adherence to ZD6474 for 6 months in patients at risk for OSCC. TERTIARY OBJECTIVES: I. Compare OSCC incidence in both study arms (ZD6474 and placebo). OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive vandetanib orally (PO) once daily (QD) for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 9 and 12 months and then every 6 months for 2 years.
Interventions
DRUGvandetanib
Given PO
OTHERplacebo
Given PO
OTHERimmunohistochemistry staining method
Correlative studies
OTHERlaboratory biomarker analysis
Correlative studies
PROCEDUREbiopsy
Correlative studies
OTHERpharmacological study
Correlative studies
Sponsors
National Cancer Institute (NCI)
University of Chicago
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histological/cytological confirmation of oral cavity dysplasia and one of three additional criteria: * Prior history of OSCC * Loss of heterozygosity (LOH) at 3p or 9p * Expression by immunohistochemistry (IHC) of budding uninhibited by benzimidazoles 3 (BUB3)/sex determining region Y (SOX4) * Provision of informed consent * Females of child bearing age must have a negative serum pregnancy test within 7 days of first dose of study drug * Patients must not have been taking steroids or are on a stable dose of steroids for at least 14 days before enrollment * Patients must have a Karnofsky Performance Score of 70% or above
Exclusion criteria
* History of malignancy within the last 5 years other than squamous cell carcinoma of the head and neck (SCCHN) and superficial non-melanoma skin cancer; patients with a history of SCCHN must be free of active carcinoma * Currently receiving treatment for any malignancy * Serum bilirubin \> 1.5x the upper limit of reference range (ULRR) * Creatinine clearance =\< 30 mL/minute (calculated by Cockcroft-Gault formula) * Potassium, \< 4.0 mmol/L despite supplementation; or above the Common Terminology Criteria for Adverse Events (CTCAE) grade 1 upper limit * Magnesium below the normal range despite supplementation, or above the CTCAE grade 1 upper limit * Serum calcium above the CTCAE grade 1 upper limit; in cases where the serum calcium is below the normal range, 2 options would be available: 1) the calcium adjusted for albumin is to be obtained and substituted for the measured serum value; exclusion is to then be based on the adjusted for albumin values falling below the normal limit; 2) Determine the ionized calcium levels; if these ionized calcium levels are out of normal range despite supplementation, then the patient must be excluded * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2.5 × ULRR * Alkaline phosphatase (ALP) \> 2.5 x ULRR * Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the Investigator's opinion makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the protocol * Clinically significant cardiovascular event (e.g. myocardial infarction, superior vena cava syndrome \[SVC\], New York Heart Association \[NYHA\] classification of heart disease \> 2 within 3 months before entry; or presence of cardiac disease that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia * History of arrhythmia (multifocal premature ventricular contractions (PVCs), bigeminy, trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation), which is symptomatic or requires treatment (CTCAE grade 3) or asymptomatic sustained ventricular tachycardia; atrial fibrillation, controlled on medication is not excluded * QTc prolongation with other medications that required discontinuation of that medication * Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age * Presence of left bundle branch block (LBBB) * QTc with Bazett's correction that is unmeasurable or ≥450 msec on screening electrocardiogram (ECG); (Note: If a subject has a QTc interval \>= 450 msec on screening ECG, the screen ECG may be repeated twice \[at least 24 hours apart\]; the average QTc from the three screening ECGs must be \< 450 msec in order for the subject to be eligible for the study) * Any concurrent medication with a known risk of inducing Torsades de Pointes, that in the investigator's opinion cannot be discontinued * Concomitant medications that are potent inducers (rifampicin, rifabutin, phenytoin, carbamazepine, phenobarbital and St. John's Wort) of Cytochrome P450 3A4 (CYP3A4) function * Hypertension not controlled by medical therapy (systolic blood pressure greater than 160 mm mercury (Hg) or diastolic blood pressure greater than 100 mm Hg) * Currently active diarrhea that may affect the ability of the patient to absorb the ZD6474 or tolerate diarrhea * Women who are currently pregnant or breast-feeding * Receipt of any investigational agents within 30 days prior to commencing study treatment * Previous enrollment or randomization of treatment in the present study * Major surgery within 4 weeks or incompletely healed surgical incision before starting study therapy * Involvement in the planning and conduct of the study (applies to both Astra Zeneca staff and staff at the study site)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison Between Treatment Groups of the Within-patient Change in MVD Score Following Treatment Initiation | Baseline to 3 months | A Wilcoxon ranksum test may be used if the normality assumption is not satisfied. Alternatively, change in MVD may be transformed (e.g. log-transformation) to satisfy the normality assumption. Additional analyses will include linear regression models with treatment effect and other prognostic factors as covariates. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Adverse Events | Weekly during treatment, up to week 24 | Adverse events rate shows the total number of subjects with an AE. |
| Number of Participants Who Adhered to Treatment | Over 6 months | Number of participants who Adhered to Treatment |
| Development of Oral and Other Cancers | At 6, 9, and 12 months and then ever 6 months for 2 years | Number of patients with new cancer |
| Biologic Effect of EGFR and VEGFR2 Inhibition | Baseline and 3 and 6 months | Effect of treatment on EGFR and VEGFR2 inhibition |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Arm I (Chemoprevention) Patients receive vandetanib PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
vandetanib: Given PO
immunohistochemistry staining method: Correlative studies
laboratory biomarker analysis: Correlative studies
biopsy: Correlative studies
pharmacological study: Correlative studies | 10 |
| Arm II (Placebo) Patients receive placebo PO QD for 6 months. Treatment continues in the absence of disease progression or unacceptable toxicity.
placebo: Given PO
immunohistochemistry staining method: Correlative studies
laboratory biomarker analysis: Correlative studies
biopsy: Correlative studies
pharmacological study: Correlative studies | 10 |
| Total | 20 |
Baseline characteristics
| Characteristic | Arm I (Chemoprevention) | Arm II (Placebo) | Total |
|---|---|---|---|
| Age, Continuous | 60.1 years STANDARD_DEVIATION 10 | 49.0 years STANDARD_DEVIATION 15 | 54.8 years STANDARD_DEVIATION 13.5 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 1 Participants | 2 Participants |
| Race (NIH/OMB) White | 9 Participants | 8 Participants | 17 Participants |
| Region of Enrollment United States | 10 participants | 10 participants | 20 participants |
| Sex: Female, Male Female | 9 Participants | 4 Participants | 13 Participants |
| Sex: Female, Male Male | 1 Participants | 6 Participants | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 10 | 0 / 10 |
| other Total, other adverse events | 8 / 10 | 6 / 10 |
| serious Total, serious adverse events | 0 / 10 | 0 / 10 |
Outcome results
Primary
Comparison Between Treatment Groups of the Within-patient Change in MVD Score Following Treatment Initiation
A Wilcoxon ranksum test may be used if the normality assumption is not satisfied. Alternatively, change in MVD may be transformed (e.g. log-transformation) to satisfy the normality assumption. Additional analyses will include linear regression models with treatment effect and other prognostic factors as covariates.
Time frame: Baseline to 3 months
Population: The outcome measure microvessel density was not collected on any subjects
Secondary
Biologic Effect of EGFR and VEGFR2 Inhibition
Effect of treatment on EGFR and VEGFR2 inhibition
Time frame: Baseline and 3 and 6 months
Population: Outcome measure was not collected.
Secondary
Development of Oral and Other Cancers
Number of patients with new cancer
Time frame: At 6, 9, and 12 months and then ever 6 months for 2 years
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm I (Chemoprevention) | Development of Oral and Other Cancers | 9 months | 0 participants |
| Arm I (Chemoprevention) | Development of Oral and Other Cancers | 18 Months | 0 participants |
| Arm I (Chemoprevention) | Development of Oral and Other Cancers | 12 months | 0 participants |
| Arm I (Chemoprevention) | Development of Oral and Other Cancers | 24 Months | 0 participants |
| Arm I (Chemoprevention) | Development of Oral and Other Cancers | 6 months | 1 participants |
| Arm II (Placebo) | Development of Oral and Other Cancers | 24 Months | 0 participants |
| Arm II (Placebo) | Development of Oral and Other Cancers | 6 months | 0 participants |
| Arm II (Placebo) | Development of Oral and Other Cancers | 9 months | 0 participants |
| Arm II (Placebo) | Development of Oral and Other Cancers | 12 months | 0 participants |
| Arm II (Placebo) | Development of Oral and Other Cancers | 18 Months | 0 participants |
Secondary
Number of Participants Who Adhered to Treatment
Number of participants who Adhered to Treatment
Time frame: Over 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Arm I (Chemoprevention) | Number of Participants Who Adhered to Treatment | 4 participants |
| Arm II (Placebo) | Number of Participants Who Adhered to Treatment | 5 participants |
Secondary
Number of Participants With Adverse Events
Adverse events rate shows the total number of subjects with an AE.
Time frame: Weekly during treatment, up to week 24
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 3 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 14 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 8 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 15 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 5 | 5 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 16 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 9 | 7 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 17 | 2 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 2 | 4 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 18 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 10 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 19 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 6 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 20 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 11 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 21 | 1 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 4 | 2 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 22 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 12 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 23 | 2 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 7 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 24 | 0 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 13 | 3 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 25 | 2 participants |
| Arm I (Chemoprevention) | Number of Participants With Adverse Events | Week 1 | 3 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 25 | 0 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 1 | 6 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 2 | 3 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 3 | 1 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 4 | 0 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 5 | 5 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 6 | 2 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 7 | 0 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 8 | 0 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 9 | 2 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 10 | 1 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 11 | 0 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 12 | 0 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 13 | 0 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 14 | 0 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 15 | 0 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 16 | 1 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 17 | 1 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 18 | 2 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 19 | 0 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 20 | 1 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 21 | 0 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 22 | 1 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 23 | 0 participants |
| Arm II (Placebo) | Number of Participants With Adverse Events | Week 24 | 0 participants |